Literature DB >> 15855526

Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol.

Muhammad Malik1, Tao Lu, Xilin Zhao, Anubha Singh, Christopher M Hattan, John Domagala, Robert Kerns, Karl Drlica.   

Abstract

Quinolones were examined for rapid lethal activity against Mycobacterium smegmatis in the presence and absence of chloramphenicol, an inhibitor of protein synthesis. C-8 methoxy, C-6 fluorine, and particular C-7 ring substituents enhanced rapid killing. With the surprising exception of moxifloxacin, higher quinolone concentrations were required for lethal activity in the presence of chloramphenicol than in its absence. Moxifloxacin was also unusual in lacking the time lag characteristic of fluoroquinolone lethality. Several fluoroquinolone dimers, which represent quinolones with large C-7 substituents, showed modest bacteriostatic activity. Unlike other quinolones, the dimers failed to display lethal activity. The insensitivity of moxifloxacin to chloramphenicol has not been observed with other bacteria and may therefore reflect unique aspects of mycobacterial gyrase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855526      PMCID: PMC1087661          DOI: 10.1128/AAC.49.5.2008-2014.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Genetic systems for mycobacteria.

Authors:  W R Jacobs; G V Kalpana; J D Cirillo; L Pascopella; S B Snapper; R A Udani; W Jones; R G Barletta; B R Bloom
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

2.  Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

Authors:  A Sugino; C L Peebles; K N Kreuzer; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

3.  Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.

Authors:  E Miyazaki; M Miyazaki; J M Chen; R E Chaisson; W R Bishai
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Dormancy of Mycobacterium tuberculosis and latency of disease.

Authors:  L G Wayne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

5.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

6.  Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.

Authors:  T Lu; X Zhao; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

7.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.

Authors:  Y Dong; C Xu; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

10.  DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.

Authors:  C R Chen; M Malik; M Snyder; K Drlica
Journal:  J Mol Biol       Date:  1996-05-17       Impact factor: 5.469

View more
  17 in total

1.  Predicting the in vivo mechanism of action for drug leads using NMR metabolomics.

Authors:  Steven Halouska; Robert J Fenton; Raúl G Barletta; Robert Powers
Journal:  ACS Chem Biol       Date:  2011-12-01       Impact factor: 5.100

Review 2.  Quinolone-mediated bacterial death.

Authors:  Karl Drlica; Muhammad Malik; Robert J Kerns; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

3.  Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Authors:  Muhammad Malik; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  A ferritin mutant of Mycobacterium tuberculosis is highly susceptible to killing by antibiotics and is unable to establish a chronic infection in mice.

Authors:  Ruchi Pandey; G Marcela Rodriguez
Journal:  Infect Immun       Date:  2012-07-16       Impact factor: 3.441

5.  Effect of anaerobic growth on quinolone lethality with Escherichia coli.

Authors:  Muhammad Malik; Syed Hussain; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

6.  Evidences for anti-mycobacterium activities of lipids and surfactants.

Authors:  Afzal Hussain; Sandeep Kumar Singh
Journal:  World J Microbiol Biotechnol       Date:  2015-12-28       Impact factor: 3.312

7.  In vitro model of mycobacterial growth arrest using nitric oxide with limited air.

Authors:  Syed Hussain; Muhammad Malik; Lanbo Shi; Maria Laura Gennaro; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.

Authors:  Nadezhda German; Muhammad Malik; Jonathan D Rosen; Karl Drlica; Robert J Kerns
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

9.  Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis.

Authors:  Jansy Sarathy; Véronique Dartois; Thomas Dick; Martin Gengenbacher
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci.

Authors:  Gregory T Robertson; Eric J Bonventre; Timothy B Doyle; Qun Du; Leonard Duncan; Timothy W Morris; Eric D Roche; Dalai Yan; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.